Letmin 5 Tablet contains Letrozole 5 mg, a non-steroidal aromatase inhibitor primarily indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women. Letrozole works by inhibiting the aromatase enzyme, which is responsible for converting androgens into estrogens, thereby reducing estrogen levels in the body. This reduction in estrogen helps to slow or reverse the growth of estrogen-dependent breast cancer cells. Letmin 5 is commonly prescribed as adjuvant therapy following surgery or radiation, as well as for advanced or metastatic breast cancer cases. The tablet should be taken orally, typically once daily, with or without food, as directed by a healthcare professional. It is essential to adhere to the prescribed dosage and duration to achieve optimal therapeutic outcomes. Common side effects may include hot flashes, fatigue, joint pain, and nausea, while serious adverse effects are rare but may include bone density loss and cardiovascular events. Patients should undergo regular monitoring, including bone health assessments, during treatment. Letmin 5 is contraindicated in premenopausal women and during pregnancy due to potential teratogenic effects. Consultation with a healthcare provider is necessary before initiating therapy to ensure appropriate use and management of potential risks.